Surrozen, Inc./DE (SRZN) Operating Margin
- Operating margin · 12 months: Value -385.28%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -385.28% | Operating income / revenue. Period ending 2026-06-30. $-44.35M ÷ $11.51M × 100 ≈ -385.28% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -44.35M USD | Operating Income (Loss) |
| Revenue | 11.51M USD | |
| Cost of products and services | (m) | |
| Research and development | 34.58M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-44.35M | $11.51M | (m) | $34.58M | (m) | -385.28% |
| 2026-03-31 | $-43.00M | $7.49M | (m) | $32.13M | (m) | -573.75% |
| 2025-12-31 | $-42.09M | $3.48M | (m) | $29.36M | (m) | -1210.58% |
| 2025-09-30 | $-38.05M | $3.60M | (m) | $25.72M | (m) | -1055.63% |
| 2025-06-30 | $-25.93M | (m) | (m) | $23.15M | (m) | (m) |
| 2025-03-31 | $-25.96M | (m) | (m) | $22.44M | (m) | (m) |
| 2024-12-31 | $-25.54M | $10.65M | (m) | $21.13M | (m) | -239.69% |
| 2024-09-30 | $-26.67M | (m) | (m) | $21.88M | (m) | (m) |
| 2024-06-30 | $-39.09M | (m) | (m) | $22.79M | (m) | (m) |
| 2024-03-31 | $-40.32M | (m) | (m) | $24.39M | (m) | (m) |
| 2023-12-31 | $-45.78M | (m) | (m) | $27.23M | (m) | (m) |
| 2023-09-30 | $-38.23M | (m) | (m) | $30.57M | (m) | (m) |
| 2023-06-30 | $-40.64M | (m) | (m) | $33.08M | (m) | (m) |
| 2023-03-31 | $-44.44M | (m) | (m) | $35.73M | (m) | (m) |
| 2022-12-31 | $-44.34M | (m) | (m) | $37.01M | (m) | (m) |
| 2022-09-30 | $-57.16M | (m) | (m) | $38.47M | (m) | (m) |
| 2022-06-30 | $-57.27M | (m) | (m) | $40.26M | (m) | (m) |
| 2022-03-31 | $-55.85M | (m) | (m) | $40.95M | (m) | (m) |
| 2021-12-31 | $-54.39M | (m) | (m) | $40.18M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |